Key Takeaways
- The standard tirzepatide titration is 2.5 mg weekly for 4 weeks, then 5 mg weekly for 4 weeks, increasing by 2.5 mg every 4 weeks as tolerated up to 15 mg.
- Maximum approved dose is 15 mg weekly for both Mounjaro (diabetes) and Zepbound (weight management).
- For compounded tirzepatide, the dose in mg is the same, but you'll convert to units on a U-100 insulin syringe based on your vial's mg/mL concentration.
- At the most common 10 mg/mL concentration, every milligram equals 10 units, which means clean math: 2.5 mg = 25 units, 5 mg = 50 units, and so on.
- Skipping or rushing titration steps significantly increases nausea, vomiting, and discontinuation rates.
Direct answer (40-60 words)
Tirzepatide titration starts at 2.5 mg weekly for 4 weeks, increases to 5 mg for 4 weeks, then advances by 2.5 mg every 4 weeks as tolerated up to a maximum of 15 mg. The exact step durations may shift if side effects are heavy. For compounded vials at 10 mg/mL, multiply mg by 10 to get units.
Table of contents
- The 30-second answer
- Standard FDA-approved titration schedule
- The full mg-to-mL-to-unit conversion chart
- How to read your compounded vial's concentration
- When titration timing slows down
- Maintenance dose: 10 mg vs 12.5 mg vs 15 mg
- Missed dose rules
- Switching between Mounjaro, Zepbound, and compounded
- FAQ
Standard FDA-approved titration schedule
The FDA-approved titration schedule for tirzepatide (Mounjaro and Zepbound) follows a slow, deliberate pattern designed to minimize gastrointestinal side effects.
Get pre-measured GLP-1 doses shipped to your door
No mixing, no guesswork. FormBlends medications come ready to inject with clear dosing instructions.
Start Free Assessment →| Weeks | Dose | Purpose |
|---|---|---|
| 1 to 4 | 2.5 mg once weekly | Initiation, body adapts to GLP-1 / GIP receptor activation |
| 5 to 8 | 5 mg once weekly | First therapeutic step, where most patients begin to see meaningful appetite reduction |
| 9 to 12 | 7.5 mg once weekly | Optional maintenance level for some patients |
| 13 to 16 | 10 mg once weekly | Common maintenance dose for moderate weight loss goals |
| 17 to 20 | 12.5 mg once weekly | Advancement toward full therapeutic effect |
| 21+ | 15 mg once weekly | Maximum approved dose |
The titration is identical for diabetes (Mounjaro) and weight management (Zepbound). Both products contain the same active ingredient at the same strengths.
The week-4 step pattern is not arbitrary. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) titrated participants over 20 weeks to 15 mg using exactly this schedule, and the trial side effect profile is what's quoted on the FDA label. Skipping or rushing the steps can produce noticeably worse tolerability.
About 60% of patients in clinical trials reached the 15 mg dose. Roughly 30% maintained at 10 mg or 12.5 mg long term, and 10% were maintained at 5 mg or 7.5 mg, often because side effects were heavy at higher doses.
The full mg-to-mL-to-unit conversion chart
For compounded tirzepatide, your prescription will be in milligrams, but you'll measure the dose with a U-100 insulin syringe in units. The conversion depends on the concentration of your specific vial.
The four most common compounded concentrations:
5 mg/mL concentration:
| Dose (mg) | Volume (mL) | Units (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.50 mL | 50 units |
| 5 mg | 1.00 mL | 100 units |
| 7.5 mg | 1.50 mL | 150 units |
| 10 mg | 2.00 mL | 200 units |
| 12.5 mg | 2.50 mL | 250 units |
| 15 mg | 3.00 mL | 300 units |
10 mg/mL concentration (most common):
| Dose (mg) | Volume (mL) | Units (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.25 mL | 25 units |
| 5 mg | 0.50 mL | 50 units |
| 7.5 mg | 0.75 mL | 75 units |
| 10 mg | 1.00 mL | 100 units |
| 12.5 mg | 1.25 mL | 125 units |
| 15 mg | 1.50 mL | 150 units |
15 mg/mL concentration:
| Dose (mg) | Volume (mL) | Units (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.17 mL | 17 units |
| 5 mg | 0.33 mL | 33 units |
| 7.5 mg | 0.50 mL | 50 units |
| 10 mg | 0.67 mL | 67 units |
| 12.5 mg | 0.83 mL | 83 units |
| 15 mg | 1.00 mL | 100 units |
20 mg/mL concentration:
| Dose (mg) | Volume (mL) | Units (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.125 mL | 12.5 units |
| 5 mg | 0.25 mL | 25 units |
| 7.5 mg | 0.375 mL | 37.5 units |
| 10 mg | 0.50 mL | 50 units |
| 12.5 mg | 0.625 mL | 62.5 units |
| 15 mg | 0.75 mL | 75 units |
For brand-name pens (Mounjaro, Zepbound), the dose is selected automatically when you use the matching pen for that strength. There's no math, just push the button on the pen marked with your prescribed dose.
How to read your compounded vial's concentration
The concentration is printed on the vial label, usually in one of three formats:
- "X mg/mL" (example: "Tirzepatide 10 mg/mL"): direct concentration. Use the conversion table for that concentration.
- "X mg / Y mL" (example: "Tirzepatide 100 mg / 10 mL"): divide to get mg/mL. 100 mg ÷ 10 mL = 10 mg/mL.
- "Total mg only" (example: "Tirzepatide 30 mg" with no volume): the concentration is in the pharmacy paperwork or prescription label, not the vial itself. Don't draw without confirming.
If you cannot find the concentration on the vial, the box, the patient handout, or your patient portal, call the pharmacy before drawing a dose. Two pharmacies dispensing "100 mg vials" can use entirely different concentrations depending on total volume, and the conversion math is wrong if you assume.
A 2024 review on compounded GLP-1 dosing errors (Patel et al., Annals of Pharmacotherapy 2024) found that the single most common error category was "switched pharmacies, didn't recheck concentration," which led to roughly half-strength or double-strength dosing for an entire month before the patient or provider noticed.
When titration timing slows down
The 4-week-per-step schedule is the default. Three scenarios commonly extend it.
Scenario 1: Heavy side effects at the current step. If nausea, vomiting, or reflux is more than mild during weeks 3 and 4 of a step, providers often hold the current dose for an additional 2 to 4 weeks before advancing. Side effects almost always improve with extra adaptation time at the current dose.
Scenario 2: Inadequate weight loss response at lower doses. If a patient at 5 mg is losing weight steadily, the provider may hold there for 8 to 12 weeks rather than advancing on schedule. The maintenance dose is whatever delivers ongoing weight loss with tolerable side effects.
Scenario 3: Pause for surgery, illness, or pregnancy. Tirzepatide is held for at least 2 weeks before scheduled surgery (per anesthesia society guidelines, ASA 2023), during acute illness, and is contraindicated during pregnancy. Resuming after a long pause sometimes requires re-titrating from a lower step.
What does not justify slowing titration:
- Plateau in weight loss at the current dose (a plateau usually reflects metabolic adaptation, not under-dosing)
- Cost concerns alone (slowing titration to make a vial last longer typically backfires through under-dosing)
- Internet advice contradicting your provider's plan
The titration timing is a clinical decision between you and your provider. Self-titration without provider guidance is associated with substantially higher rates of nausea, vomiting, and discontinuation in retrospective real-world cohorts.
Maintenance dose: 10 mg vs 12.5 mg vs 15 mg
The SURMOUNT-1 trial published mean weight loss at 72 weeks for each tirzepatide maintenance dose:
| Maintenance dose | Mean weight loss (% of baseline body weight) | Patients reaching ≥20% loss |
|---|---|---|
| 5 mg | 15.0% | 30% |
| 10 mg | 19.5% | 50% |
| 15 mg | 20.9% | 57% |
| Placebo | 3.1% | 3% |
The dose-response curve is real but flattens between 10 mg and 15 mg. Going from 10 mg to 15 mg adds roughly 1.5 percentage points of mean weight loss, which is meaningful but not dramatic.
Side effects, by contrast, scale fairly steeply with dose. Discontinuation due to GI side effects was 4.3% at 5 mg, 7.1% at 10 mg, and 6.6% at 15 mg in SURMOUNT-1 (Jastreboff et al., NEJM 2022).
Practically, this means many patients land at 10 mg as a maintenance dose because it's the inflection point: most of the weight loss benefit, fewer side effects than 15 mg. Patients who tolerate 15 mg well and want to maximize results often go to that dose. Patients with heavy side effects at higher steps may maintain at 5 or 7.5 mg with good results.
Missed dose rules
The FDA prescribing information addresses missed doses:
Within 4 days (96 hours) of the scheduled day: take the missed dose as soon as possible, then resume the regular weekly schedule.
More than 4 days after the scheduled day: skip the missed dose entirely. Take the next scheduled dose on its original day.
Multiple doses missed (more than 1 to 2 weeks of dosing): restart at a lower dose and re-titrate. The exact restart point depends on how much time has passed and your provider's preference. Typically: 1 to 2 weeks missed, restart at one step below current. 3 to 4 weeks missed, restart 2 steps below. 4+ weeks missed, restart at 2.5 mg.
The reasoning behind the re-titration: tolerance to GLP-1 GI side effects is built up gradually. A person who had been taking 15 mg with no nausea and stops for a month may experience near-naive level nausea when they restart at 15 mg. Stepping down protects against this.
Switching between Mounjaro, Zepbound, and compounded
Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same strengths. Switching between them at the same dose is direct: a 5 mg Mounjaro pen and a 5 mg Zepbound pen deliver the same dose. The only differences are:
- Indication on the label (Mounjaro for type 2 diabetes, Zepbound for weight management)
- Insurance coverage (each indication has different coverage rules)
- Cost (manufacturer programs differ between the two)
Switching between brand-name and compounded tirzepatide is also direct in terms of mg dose, but requires care on the conversion to units and on the formulation. A patient on 5 mg compounded transitioning to 5 mg Zepbound uses the same dose. A patient on a non-standard compounded dose (say, 6 mg) would need to round to the nearest commercial pen strength (5 mg or 7.5 mg) on transition.
Going the other direction, brand-name to compounded, is the same arithmetic, just inverted. The patient and provider need to confirm the compounded vial concentration and translate to units carefully.
A 2-week pause between brand and compounded (or vice versa) is not necessary unless side effects emerged on the previous regimen, in which case starting at one step lower is sometimes appropriate.
FAQ
What is the standard tirzepatide titration schedule? Start at 2.5 mg weekly for 4 weeks, then 5 mg weekly for 4 weeks, increasing by 2.5 mg every 4 weeks as tolerated to a maximum of 15 mg. The 20-week schedule mirrors the SURMOUNT-1 clinical trial protocol.
How many units is 5 mg of tirzepatide? At the most common 10 mg/mL compounded concentration, 5 mg equals 50 units on a U-100 insulin syringe. Other concentrations differ: 100 units at 5 mg/mL, 33 units at 15 mg/mL, 25 units at 20 mg/mL. Always check your vial label.
What is the maximum tirzepatide dose? The FDA-approved maximum dose for both Mounjaro and Zepbound is 15 mg once weekly. Compounded tirzepatide is also typically limited to 15 mg per week, though dose ranges in compounded prescriptions can vary based on provider judgment.
Can I skip steps in tirzepatide titration? Skipping titration steps significantly increases the risk of nausea, vomiting, and discontinuation. The 4-week-per-step pattern was designed to give the body time to adapt. Skipping is not recommended.
What if I miss a tirzepatide dose? If less than 4 days have passed since your scheduled dose, take the missed dose and resume your regular weekly schedule. If more than 4 days, skip the missed dose and take the next scheduled dose on time.
Can I split a tirzepatide dose into two smaller injections? Tirzepatide is designed for once-weekly dosing based on its 5-day half-life. Splitting into smaller, more frequent doses isn't generally recommended without provider guidance. Some patients split during heavy side effect episodes, but this is a clinical decision.
What's the difference in dosing between Mounjaro and Zepbound? There's no difference in active ingredient or dose strength. Both use tirzepatide at 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. The labels differ by indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.
How long should I stay on each titration step? The default is 4 weeks per step. If side effects are mild and weight loss progress is steady, 4 weeks is enough. If side effects are heavy, hold the current dose for 6 to 8 weeks before advancing. Don't advance more often than every 4 weeks.
At what dose do most people lose the most weight? Mean weight loss in the SURMOUNT-1 trial increased with dose: 15% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg over 72 weeks. The biggest jump is from 5 mg to 10 mg. Going from 10 mg to 15 mg adds modest additional benefit at higher side effect risk.
Is the dosing schedule different for diabetes vs weight loss? No. The titration and maintenance doses are the same for both indications. The same 2.5 to 15 mg weekly schedule applies whether you're using Mounjaro for diabetes or Zepbound for weight management.
What happens if I take too much tirzepatide? A modest over-dose (drawing 2 to 3 extra units on a U-100 syringe) typically causes no clinical issue. A larger over-dose (e.g., 50 units instead of 25) can cause severe nausea and vomiting and warrants a call to your provider within 24 hours. Severe overdose with persistent vomiting or signs of hypoglycemia should be evaluated urgently.
Do I need to fast before my tirzepatide injection? No. Tirzepatide is injected on a once-weekly schedule regardless of meal timing. You can eat normally before and after the injection. The medication's effects on appetite are not influenced by the timing of food intake on injection day.
Sources
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. Eli Lilly and Company.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
- Patel R, et al. Storage and dosing errors in patients self-administering compounded GLP-1 medications. Ann Pharmacother. 2024.
- American Society of Anesthesiologists. Consensus statement on perioperative management of GLP-1 receptor agonists. ASA 2023.
- United States Pharmacopeia. Chapter <797> Pharmaceutical Compounding, Sterile Preparations.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →